Eli Lilly (LLY) stock falls slightly after unveiling a $2.88B cash deal to acquire Merida Biosciences, gaining access to promising autoimmune therapies. The post Eli Lilly (LLY) Stock Edges Lower as $2.88B Merida Biosciences Acquisition Announced appeared first on Blockonomi.